Literature DB >> 28299020

Authors' Reply.

Sri Ramakrishnan1, Balakrishnan Kannan1, Aarathy Kannan2, E Prasanna Venkatesan3.   

Abstract

Entities:  

Year:  2017        PMID: 28299020      PMCID: PMC5340056          DOI: 10.4103/2008-322X.200165

Source DB:  PubMed          Journal:  J Ophthalmic Vis Res        ISSN: 2008-322X


× No keyword cloud information.
Dear Editor, Hemodynamic dysregulation due to autonomic nerves involvement is common in Guillain-Barre syndrome (GBS). About 61% of patients suffering from GBS have transient hypertension and 43% have postural hypertension.[1] Persistent hypertension is not a prerequisite for posterior reversible encephalopathy syndrome (PRES) and 15 to 20% of subjects with PRES are normotensive or hypotensive.[2] Transient hypertension is sufficient to disrupt the autoregulation and lead to PRES. Moreover, the upper limit for autoregulation varies between different individuals. Our patient did not have persistent hypertension, but could have had transient hypertension. In the literature, there are 5 case reports of PRES following IVIG. Mathy et al reported PRES on the first day of IVIG, and Voltz et al described PRES after 3 days of IVIG. Doss-Esper et al reported PRES and reversible cerebral vasoconstriction syndrome leading to stroke after one day administration of IVIG, Koichihara et al described PRES in a 14-year-old girl 3 days after IVIG, and Faruk Incecik et al reported PRES after 5 days of IVIG. Actually, all patients developed PRES within 5 days of IVIG treatment. Although these patients were diagnosed to develop PRES related to IVIG, transient autonomic disturbance secondary to GBS could also have contributed to PRES.[34567] In the study conducted by Doss-Esper et al, the patient developed acute hypertension after IVIG. Our patient developed PRES following 10 days of IVIG treatment which makes it an improbable cause for PRES. PRES has been reported to be associated with other autoimmune diseases, such as neuromyelitis optica spectrum disorders, autoimmune thyroid disease and systemic lupus erythematosus.[8910] Further research is required to explain the occurrence of PRES with GBS and other autoimmune disorders. Based on just few case reports, we would not conclude that PRES precedes GBS. We believe PRES can either precede or occur during the course of GBS. GBS with dysautonomia can be considered as an independent risk factor for PRES.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  9 in total

1.  Blood pressure fluctuations in posterior reversible encephalopathy syndrome.

Authors:  Alejandro A Rabinstein; Jay Mandrekar; Ryan Merrell; Osman S Kozak; Olayemi Durosaro; Jennifer E Fugate
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-05-04       Impact factor: 2.136

2.  Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders.

Authors:  S M Magaña; M Matiello; S J Pittock; A McKeon; V A Lennon; A A Rabinstein; E Shuster; O H Kantarci; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

3.  Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in guillain-barre syndrome.

Authors:  Christine E Doss-Esper; Aneesh B Singhal; Marsha S A Smith; Galen V Henderson
Journal:  J Neuroimaging       Date:  2005-04       Impact factor: 2.486

4.  A case of autoimmune thyroid disease presenting posterior reversible encephalopathy syndrome.

Authors:  Yohei Tateishi; Yasuyuki Iguchi; Kazumi Kimura; Junya Aoki; Junichi Uemura; Kensaku Shibazaki
Journal:  J Neurol Sci       Date:  2008-05-13       Impact factor: 3.181

5.  Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin.

Authors:  R Voltz; F V Rosen; T Yousry; J Beck; R Hohlfeld
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

6.  Posterior reversible encephalopathy syndrome associated with IVIG in a patient with Guillain-Barré syndrome.

Authors:  Reiko Koichihara; Shin-Ichiro Hamano; Shintaro Yamashita; Manabu Tanaka
Journal:  Pediatr Neurol       Date:  2008-08       Impact factor: 3.372

Review 7.  Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature.

Authors:  I Mathy; M Gille; F Van Raemdonck; J Delbecq; A Depré
Journal:  Acta Neurol Belg       Date:  1998-12       Impact factor: 2.396

Review 8.  Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature.

Authors:  G Leroux; J Sellam; N Costedoat-Chalumeau; D Le Thi Huong; A Combes; N Tieulié; J Haroche; Z Amoura; A Nieszkowska; J Chastre; D Dormont; J-C Piette
Journal:  Lupus       Date:  2008-02       Impact factor: 2.911

9.  Reversible posterior encephalopathy syndrome due to intravenous immunoglobulin in a child with Guillain-Barré syndrome.

Authors:  Faruk Incecik; M Ozlem Hergüner; Sakir Altunbasak; Dincer Yıldızdas
Journal:  J Pediatr Neurosci       Date:  2011-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.